Anti-oxMIF Programs

About OncoOne

OncoOne is a private, preclinical-stage biotech based in Vienna, Austria, pioneering next-generation targeted cancer therapies. The company's core assets are two distinct but complementary technology platforms: the Anti-oxMIF platform targeting a novel tumor-associated form of the macrophage migration inhibitory factor (MIF), and the PreTarg-it® platform, a modular system for pre-targeted radioimmunotherapy designed to enhance precision and safety. Currently seeking Series A+/B financing and strategic partnerships, OncoOne aims to advance its pipeline of highly differentiated candidates into clinical development for oncology and chronic inflammatory diseases.

Therapeutic Areas